Almirall Showcases Therapeutic Innovations at AAD 2025

Image Credit: © Timon - stock.adobe.com

At the 2025 American Academy of Dermatology (AAD) Annual Meeting, Almirall presented 5 scientific posters, including new data on tirbanibulin, a topical treatment for actinic keratosis (AK), and updates on its early-stage clinical development asset LAD191, a high-affinity monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP).¹

"Our close collaboration with the dermatology community and patients allows us to better understand their needs and develop effective solutions. The findings presented at AAD 2025 show our focus on delivering impactful data on our established products as well as progressing our early-stage pipeline. The data on tirbanibulin for the treatment of actinic keratosis highlight the importance of a patient-centered approach to achieve treatment success. Presenting data from the phase I study of our early-stage asset LAD191 is an important step towards adding new impactful treatments to our dermatology portfolio in the future," stated Volker Koscielny, MD, MBA, Almirall’s chief medical officer, in a news release from the company.

Tirbanibulin: Efficacy and Patient Satisfaction

New data analysis on tirbanibulin underscores its effectiveness in treating AK. Findings from phase III, phase IV, and real-world evidence studies confirm high treatment response rates and patient satisfaction. The studies demonstrate that tirbanibulin provides a favorable safety and tolerability profile, reinforcing its role as a reliable therapeutic option for AK.

Darrell Rigel, MD, MS, clinical professor at the Mount Sinai Icahn School of Medicine, emphasized the importance of patient experience in dermatological treatments in the release, stating, "Patient satisfaction is a significant aspect of treatment outcomes. The results of these studies with tirbanibulin indicate notable improvements in patient satisfaction in real-world scenarios, which supports adherence to AK treatment protocols. By prioritizing patient experience and addressing their needs, the effectiveness of therapies can be enhanced, leading to an overall improvement in quality of care."

Almirall’s research also highlights how patient-reported satisfaction correlates with clinical efficacy, suggesting that well-tolerated treatments with manageable adverse effects can improve adherence and overall therapeutic success.

LAD191: Advancing Immune-Modulated Skin Disease Treatments

Almirall also presented early-stage clinical data on LAD191, a novel monoclonal antibody targeting IL-1RAP, which plays a key role in immune-modulated skin conditions such as hidradenitis suppurativa. The phase I study, conducted in healthy volunteers, demonstrated a favorable safety and tolerability profile, supporting continued clinical development. LAD191's mechanism of action involves blocking multiple proinflammatory pathways, potentially offering greater clinical benefit compared to single-cytokine inhibitors.

Addressing Unmet Needs in Dermatology

Medical dermatology continues to face significant unmet needs, with many conditions having limited treatment options. Almirall’s contributions at AAD 2025 emphasize its focus on research and innovation to improve the quality of life for patients with dermatological diseases. The company’s investment in advanced biologic solutions for conditions such as psoriasis and atopic dermatitis reflects its commitment to delivering transformative dermatological therapies.

Almirall at AAD 2025

Almirall’s engagement at AAD 2025 includes participation in scientific discussions and collaboration with healthcare professionals and industry peers. The company’s 5 accepted abstracts include:

• Patient outcomes and satisfaction with tirbanibulin for the treatment of actinic keratosis (AK): Results from real-world studies.
• Relating patient-reported treatment satisfaction and clinical outcomes in real-world studies of tirbanibulin for AK.
• Safety and tolerability of tirbanibulin for AK: Results from clinical trials and real-world studies.
• Clearance of AK with tirbanibulin: Comparing results from controlled trials with real-world clinical studies.
• Phase I study of LAD191: Assessing the safety, tolerability, and pharmacokinetics of a monoclonal antibody targeting IL-1RAP in healthy volunteers.

Conclusion

With over 80 years of experience in healthcare, Almirall’s presence at AAD 2025 underscores its commitment to delivering solutions that enhance patient care and treatment outcomes. Through its ongoing efforts in dermatological research and development, Almirall stated it continues to work toward the future of medical dermatology, striving to meet the evolving needs of patients and health care professionals.

Reference

AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with tirbanibulin. News Release. Business Wire. Published March 7, 2025. Accessed March 7, 2025. https://www.businesswire.com/news/home/20250307364570/en/AAD-2025-Almirall-presents-early-stage-pipeline-progress-and-real-world-evidence-on-demonstrating-AK-treatment-success-and-patient-satisfaction-with-Tirbanibulin